Condition: Locally Advanced Unresectable or Metastatic Gastric Cancer · Sponsor: Akeso
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
This description comes directly from the study's public registry record.
Zhifang Yao，MD · 86-0760-89873999 · clinicaltrials@akesobio.com
Jiafu Ji, MD · jijiafu@hsc.pku.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07547787